How would you approach treatment for EGFR-mutant NSCLC with acquired ERBB2 mutation and amplification as resistance to prior osimertinib-based therapy?

What are your thoughts on the safety and efficacy of continuing osimertinib in combination with other systemic therapies in this setting? For systemic options, would you consider the MARIPOSA-2 regimen, zongertinib, or other approaches?

Please select the option that best describes you:

How would you approach treatment for EGFR-mutant NSCLC with acquired ERBB2 mutation and amplification as resistance to prior osimertinib-based therapy?

Related Questions